Grant Awarded For Study of Tumor-Specific DNA Mutations Involved in Colorectal Cancer
Feb 24, 2005 - 7:00:00 AM
The large-scale identification and characterization of genes mutated in cancer will advance our understanding of the mechanisms by which malignant cells arise from their normal progenitors, stated Andrew Sparks, PhD, Director of Association Studies at Perlegen Sciences and Principle Investigator of the study.
By Akanksha, Pharmacology Correspondent, [RxPG] Perlegen Sciences, Inc. announced today that it has been awarded a grant from the National Cancer Institute (NCI) to study tumor-specific DNA mutations involved in colorectal cancer in collaboration with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The research could lead to a better understanding of the disease, improved tools for cancer detection and diagnosis, new targets for therapeutic and preventive intervention, and opportunities for more individualized treatment.
In an effort to identify and characterize cancer genes, the team will analyze at single-base resolution the DNA sequences of thousands of genes in colorectal tumor tissue as well as in normal tissue from the same patients.
This effort is expected to lead to the identification of a significant number of tumor-specific mutations, providing insight into the cause of disease.
The large-scale identification and characterization of genes mutated in cancer will advance our understanding of the mechanisms by which malignant cells arise from their normal progenitors, stated Andrew Sparks, PhD, Director of Association Studies at Perlegen Sciences and Principle Investigator of the study. We are excited to be working on this important issue with the distinguished cancer investigators at Johns Hopkins.
Perlegen Sciences, Inc. is working to provide safe and effective medicines to the world. The company quickly and cost effectively analyzes millions of unique genetic variations in DNA samples obtained from clinical trial participants. This information is used to explain and predict the efficacy and adverse effect profiles of prescription drugs. Perlegen also applies this expertise to discovering genetic variants associated with disease for potential new therapeutics and diagnostics. For years, scientists and drug manufacturers have been eager to comprehensively examine entire genomes; through Perlegen, this is now possible. Perlegen is able to bring pharmaceutical products to the market wherein clinical development could have been otherwise discontinued.For more information kindly visit the company's website.
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use